Psoriasis
Conference Coverage
Adalimumab May Be Best Anti-TNF for Psoriasis in Obesity
Conference Coverage
Brodalumab Knocks Psoriasis Out of Park
Major Finding: After 48 weeks of treatment with brodalumab, 60% of patients with moderate to severe psoriasis displayed a PASI 100 response.Data...
Conference Coverage
Thalidomide Remains a Good Choice for Refractory Cutaneous Lupus
News
Antibiotics Helpful in Chlamydia-Induced Reactive Arthritis
News
Using CORRONA Registry Data to Treat Rheumatic Diseases
Conference Coverage
Severe Psoriasis Linked to Doubled Diabetes Risk
Major Finding: New-onset, severe psoriasis doubled the risk for incident diabetes during a median of 6 years compared with people without...
Conference Coverage
Antimalarial Response in CLE Takes Time
Conference Coverage
Psoriasis Severity Linked to Tonsil Size
Major Finding: Patients with psoriasis had an odds ratio of 8.77 for having enlarged tonsils (grade 2 or greater), compared with healthy controls...
News
Anti-TNF Use Linked to Cardiovascular-Disease Drop in RA
Conference Coverage
Psoriasis Patients Still Going Unscreened for Heart Disease
Major Finding: Approximately 41% of psoriasis patients were screened for at least one of four risk factors for cardiovascular disease during...